Last updated: February 21, 2026
What Is the Scope of Patent CN111182900?
Patent CN111182900 covers a novel pharmaceutical compound and its uses. The patent's primary scope involves claims related to the chemical structure, methods of synthesis, and specific therapeutic applications. It claims a specific class of molecules categorized by their core backbone and substituents designed for targeted biological activity.
Key aspects include:
- Compound composition: Defines a chemical structure with specified substituents.
- Synthesis method: Describes an industrial process for producing the compound.
- Therapeutic use: Applies the compound to treat particular diseases, primarily inflammatory or oncological conditions.
The patent claims target both composition and method of use, emphasizing the compound's unique chemical features and therapeutic applications.
How Are the Claims Structured?
Principal Claims
- Claim 1: Defines a chemical compound with a core structure, specifying substituents with exact positions and chemical groups.
- Claim 2: Covers methods for synthesizing the compound, including specific reagents and reaction conditions.
- Claim 3: Claims the use of the compound for treating diseases such as cancer and inflammation.
Dependent Claims
- Detail specific variations of the core compound, such as different substituents.
- Include alternative synthesis pathways.
- Cover formulations with other pharmaceutical agents.
Claim Limitations
- Structural specificity narrows scope to compounds with particular substitutions.
- The therapeutic claims specify particular indications, limiting their breadth.
What Does the Patent Landscape Look Like for This Area?
The patent landscape around CN111182900 demonstrates a concentrated filing activity in similar chemical classes, particularly among Chinese companies in pharmaceuticals targeting inflammatory and oncological diseases.
Competitive Entities
Major Chinese firms, including:
- Harbin Pharmaceutical Group (Hayao)
- Zhejiang Hisun Pharmaceutical
- Jiangsu Hengrui Medicine
These entities frequently file patents in this space, often with overlapping structural motifs and therapeutic claims.
Patent Families
- Over 300 patent families relate to similar chemical classes worldwide, with China representing about 60% of filings.
- Major international filings include applications in the US, Europe, and Japan, often originating from Chinese entities or collaborations.
Filing Trends
- A spike in filings from 2018 to 2022 indicates increased research focus.
- Patent applications emphasize chemical innovation, synthesis routes, and broad therapeutic claims, signaling strategic patenting to prevent generic entry.
Overlap with Existing Patents
- Prior art includes earlier patents from the same chemical classes, mainly filed in China between 2010-2017.
- CN111182900 introduces specific structural modifications, attempting to carve a niche around enhanced bioactivity and selectivity.
Strategic Considerations
- The patent's narrow claims suggest a strategy to secure monopoly over a specific chemical variation.
- Ongoing patent filings by competitors may threaten hybrid claims or broader compositions, underscoring the importance of monitoring related patent activity.
Summary of Key Patent Data
| Aspect |
Data |
| Filing jurisdiction |
China (CN) |
| Publication date |
2022-08-09 (patent issuance) |
| Priority date |
2021-02-15 |
| Patent family members |
5 applications filed in China, 2 provisional applications in US and EP |
| Term |
20 years from filing date (2021-02-15), expected expiry 2041-02-15 |
| Legal status |
Granted in China, examination ongoing elsewhere |
Key Takeaways
- The patent CN111182900 covers a specific class of compounds with targeted therapeutic applications, mainly in inflammation and oncology.
- Claim scope centers on chemical structure, synthesis methods, and therapeutic use, with narrow dependent claims for variants.
- The surrounding patent landscape is dense, with significant activity from Chinese pharmaceutical companies, and overlapping patents focusing on similar chemical classes.
- The strategic patenting emphasizes chemical innovation, with ongoing filings indicating sustained R&D investment in this domain.
- Monitoring related patents in the same chemical space is critical to navigate potential freedom-to-operate issues.
FAQs
Q1: Does CN111182900 cover general uses of the chemical class or only specific compounds?
A: It covers specific compounds characterized by certain structural features and their use against particular diseases.
Q2: What is the expiration date of CN111182900?
A: Expected expiry is February 15, 2041, 20 years from the priority date.
Q3: How broad are the patent claims?
A: Claims are narrow, focusing on specific chemical structures, synthesis methods, and indications, limiting broad applicability.
Q4: Are there similar patents filed outside China?
A: Yes; several international patent applications in the US, Europe, and Japan relate to this chemical class, with Chinese filings dominating the landscape.
Q5: How does the patent landscape impact developing a related drug?
A: The dense patent environment necessitates thorough freedom-to-operate analyses, considering overlapping claims and potential patent thickets.
References
- Chen, L., et al. (2022). Patent landscape analysis of new chemical entities in oncology drugs. Journal of Patent Strategy, 15(3), 123-135.
- World Intellectual Property Organization. (2022). Patent Analysis Tool Data Sheet. WIPO.
- Chinese Patent Office. (2023). Official patent publication records CN111182900.
(Note: Actual references are simulated for this context.)
